DexCom (NASDAQ: DXCM) — Company Overview, News & Financial Data
DexCom develops continuous glucose monitoring systems, enhancing diabetes management through real-time monitoring and innovative technology.
DexCom
DexCom is a medical device company that designs, develops, and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and health-conscious individuals. Headquartered in San Diego, California, the company produces biosensors, transmitters, and mobile applications that enable users to track real-time blood glucose levels continuously without routine fingersticks. Its core product lines include continuous glucose monitoring systems and over-the-counter glucose biosensors. DexCom serves patients, healthcare providers, and distributors across the United States and international markets.
Snapshot
Operations
Products and/or services of DexCom
- Continuous Glucose Monitoring Systems: Wearable sensor hardware and transmitters attached to the body to measure subcutaneous glucose levels in real time, delivering automated readings to dedicated receivers and paired mobile applications for insulin-dependent diabetes management.
- Over-the-Counter Glucose Biosensors: Wearable non-prescription sensing devices designed for adults not taking insulin, allowing health-conscious users and individuals with type 2 diabetes to track glucose trends, dietary responses, activity impacts, and metabolic patterns.
- Software and Mobile Applications: Mobile tracking applications and digital cloud platforms that display continuous glucose data, send custom high and low glucose alerts, allow remote monitoring by caregivers, and aggregate historical health data for personal insights.
- Data Analytics and Clinical Portals: Web-based software solutions for healthcare providers to review patient continuous glucose data, generate comprehensive clinical reports, analyze glycemic trends, and optimize diabetes treatment plans during routine clinical consultations and remote care.
- Automated Insulin Delivery Integration: Technical integration protocols and software partnerships with automated insulin delivery pumps and smart insulin pens, enabling automated closed-loop insulin dosing based on real-time continuous sensor readings.
- International Distribution and Commercialization: Global supply and commercialization operations spanning North America, Europe, Asia-Pacific, and Latin America, supplying direct-to-consumer channels, pharmacy networks, durable medical equipment distributors, and international healthcare systems.
DexCom executive team
- Mr. Jacob Steven LeachPresident, CEO & Director
- Mr. Kevin Ronald SayerExecutive Chairman of the Board (Leave of Absence)
- Mr. Jereme M. Sylvain CPAExecutive VP, CFO & Chief Accounting Officer
- Mr. Michael Jon BrownExecutive VP & Chief Legal Officer
- Ms. Sadie M. SternExecutive VP & Chief Human Resources Officer
- Mr. Girish NaganathanExecutive VP & CTO
- Mr. Sean ChristensenVice President of Finance and Investor Relations
- Mr. Matthew DolanExecutive Vice President of Strategy & Corporate Development
- Mr. Donald M. AbbeyExecutive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs
- Mr. Jon ColemanExecutive VP & Chief Commercial Officer